Hikma Pharmaceuticals Regulatory News (HIK)

Hikma Pharmaceuticals PLC - LTIP Awards

LONDON, 15 May 2015: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) announces that the Remuneration Committee has made the following conditional awards under the Hikma Pharmaceuticals PLC 2014 Executive Incentive Plan (the "EIP") to certain Persons Discharging Managerial Responsibility ("PDMR") of the Company.

Following shareholder approval at the AGM on 14 May 2015, the awards under the EIP were made automatically on 15 May 2015 at a price of 1,981 pence per Ordinary Share (being the average price for the 30 day period prior to 31 December 2014, in accordance with the EIP rules) as follows:

The Element B share awards will be released to the participants in two years' time subject to their continued employment and the non-occurrence of forfeiture events during the vesting period as judged by the Remuneration Committee at each anniversary of the grant.

The Element C share awards will be released to the participants in three years' time subject to their continued employment.

These participants are not allowed to sell 50% of the vested shares under elements B and C until five years.

Further details on the EIP, forfeiture criteria and holding period can be found in Hikma's report and accounts for the year ended 31 December 2014 on pages 98, 103 and 104.

- ENDS -

Enquiries:

Hikma Pharmaceuticals PLC

Peter Speirs +44 20 7399 2760

Company Secretary

About Hikma

Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2014, Hikma achieved revenues of $1,489 million and profit attributable to shareholders of $278 million.